GlassScriptPhysician profile
William Robert Pitts
NPI 1891799300
$9,939.39
in general payments reported to CMS, 2019-2025
29 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,424 · 2020: $1,638 · 2021: $920 · 2022: $2,117 · 2023: $1,013 · 2024: $1,563 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,841.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,493.06 | 2020-2025 | Indigo System |
| Medtronic Vascular, INC. | $1,269.58 | 2019-2020 | |
| Medtronic, INC. | $1,266.35 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Abbott Laboratories | $1,026.20 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Dragonfly Opstar |
| Boston Scientific Corporation | $601.17 | 2020-2025 | Avvigo Guidance System, Farapulse |
| Philips North America LLC | $483.95 | 2019-2023 | |
| Shockwave Medical, INC | $451.29 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $419.38 | 2019-2025 | |
| Abiomed | $384.02 | 2019-2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $293.62 | 2021-2023 | |
| Biotronik INC. | $247.73 | 2023-2025 | Orsiro Mission |
| Pfizer INC. | $236.93 | 2019-2024 | |
| Novo Nordisk INC | $215.04 | 2020-2024 | Rybelsus, Ozempic |
| Cardiovascular Systems INC. | $185.90 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $171.25 | 2019-2024 | Camzyos, Eliquis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $169.18 | 2025 | Orsiro Mission |
| Celonova Biosciences, INC. | $146.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $141.89 | 2019-2023 | Farxiga |
| Impulse Dynamics (USA) INC. | $130.82 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $126.04 | 2019-2024 | Opsumit, Uptravi |
| Acist Medical Systems, INC. | $120.00 | 2021 | |
| Amgen INC. | $88.67 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.09 | 2019 | |
| Amarin Pharma, INC. | $66.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $41.73 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $34.75 | 2025 | Rotarexs 6 F X 135 Cm |
| Angiodynamics, INC. | $24.79 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $18.35 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $14.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.